| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 1.08 | 20.0% | 97.7% |
| Total Income | 1.08 | 20.0% | 97.7% |
| Expenditure | 6.49 | 51.6% | 89.7% |
| PBT | -13.15 | 4.6% | 26.8% |
| Net Profit | 200.64 | 2740.0% | 1274.7% |
| OPM | — | ||
| NPM | 100.00% | 136.87pp | |
| EPS | 49.61 | 2738.8% | 29282.3% |
FibroGen Reports Q3 2025 Financial Results; Revenue at $1.1 Million
04 May 2026 · 4 May, 7:34 am
Summary
FibroGen, Inc. reported financial results for the third quarter of 2025. Total revenue from continuing operations was $1.1 million, an increase from $0.1 million in the same quarter of the previous year. The net loss from continuing operations was $13.1 million, a significant decrease from the $48.3 million loss in the third quarter of 2024. The company's cash, cash equivalents, accounts receivable, and investments totaled $121.1 million. FibroGen anticipates that these funds will sustain operating plans into 2028.
Key Highlights
- 1
FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million.
- 2
The Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), has been initiated.
- 3
An agreement with the U.S. Food and Drug Administration (FDA) was reached on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS).
- 4
Total revenue from continuing operations for the third quarter of 2025 was $1.1 million, compared to $0.1 million for the third quarter of 2024.
- 5
Net loss from continuing operations for the third quarter of 2025 was $13.1 million, or $3.25 loss per basic and diluted share, compared to a loss of $48.3 million one year ago.
- 6
FibroGen reported cash, cash equivalents, accounts receivable, and investments of $121.1 million as of September 30, 2025.
- 7
The company expects its cash, cash equivalents, accounts receivable, and investments to be sufficient to fund operating plans into 2028.
Management Comments
Thane Wettig
With the completion of the transformative sale of our FibroGen China operations, we have significantly simplified our capital structure and extended our cash runway into 2028. Notably, we initiated the Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis anticipated in the second half of 2026. We remain on track to submit the Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025 and continue to assess its development options. We are excited to continue building on the strong momentum we have gained throughout this year.
Informational and educational content only. Not investment advice.